Item 1.01 Entry into a Material Definitive Agreement.

On April 4, 2023, BioCorRx Inc., a Nevada corporation (the "Company"), entered into a Subscription Agreement (the "Subscription Agreement") with an accredited investor (the "Investor"). Pursuant to the Subscription Agreement, the Investor (i) purchased shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), in the aggregate amount of $300,000 at a purchase price of $1.72 per share, for a total of 174,409 shares of Common Stock and (ii) was issued a warrant to purchase up to 174,409 shares of Common Stock (the "Warrant"). The Warrant is exercisable for three (3) years from the date of issuance at an exercise price of $4 per share.

The foregoing description of the Subscription Agreement and the Warrant does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the form of the Subscription Agreement and the Warrant, copies of which are attached hereto as Exhibit 10.1 and Exhibit 4.1, respectively, and incorporated herein by reference.






2

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.

The following documents are filed as exhibits to this current report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the Commission filing that included such document.





Exhibit  No.   Description
  4.1            Form of Warrant
  10.1           Form of Subscription Agreement by and between BioCorRx Inc. and
               the Investor
104            Cover Page Interactive Data File (formatted as inline XBRL).





3

© Edgar Online, source Glimpses